Combined Yeast β-Glucan and Antitumor Monoclonal Antibody Therapy Requires C5a-Mediated Neutrophil Chemotaxis via Regulation of Decay-Accelerating Factor CD55
Authors:
Open Access
- 1 August 2007
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 67 (15) , 7421-7430
Abstract
Administration of a combination of yeast-derived β-glucan with antitumor monoclonal antibodies (mAb) has significant therapeutic efficacy in a variety of syngeneic murine tumor models. We have now tested this strategy using human carcinomas implanted in immunocompromised severe combined immunodeficient mice. Combined immunotherapy was therapeutically effective in vivo against NCI-H23 human non–small-cell lung carcinomas, but this modality was surprisingly ineffective against SKOV-3 human ovarian carcinomas. Whereas NCI-H23 tumors responded to this combination therapy with increased intratumoral neutrophil infiltration and C5a production, these responses were lacking in treated SKOV-3 tumors. Further results suggested that SKOV-3 tumors were protected by up-regulation of the membrane complement regulatory protein CD55 (decay-accelerating factor). Blockade of CD55 in vitro led to enhanced deposition of C activation product C3b and increased cytotoxicity mediated by β-glucan–primed neutrophils. In vivo, administration of anti-CD55 mAb along with β-glucan and anti–Her-2/neu mAb caused tumor regression and greatly improved long-term survival in animals bearing the previously resistant SKOV-3 tumors. This was accompanied by increased intratumoral neutrophil accumulation and C5a production. We conclude that CD55 suppresses tumor killing by antitumor mAb plus β-glucan therapy (and, perhaps, in other circumstances). These results suggest a critical role for CD55 to regulate iC3b and C5a release and in turn to influence the recruitment of β-glucan–primed neutrophils eliciting killing activity. [Cancer Res 2007;67(15):7421–30]Keywords
This publication has 48 references indexed in Scilit:
- Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndromeMolecular Immunology, 2007
- Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomasJournal of Oral Pathology & Medicine, 2006
- Targeting HER2 EpitopesSeminars in Oncology, 2006
- Cross‐linking tumor cells with effector cells via CD55 with a bispecific mAb induces β‐glucan‐dependent CR3‐dependent cellular cytotoxicityEuropean Journal of Immunology, 2006
- ß-glucan affects leukocyte navigation in a complex chemotactic gradientSurgery, 2004
- Tumor-Specific Inhibition of Membrane-Bound Complement Regulatory Protein Crry with Bispecific Monoclonal Antibodies Prevents Tumor Outgrowth in a Rat Colorectal Cancer Lung Metastases ModelCancer Research, 2004
- Cetuximab in Advanced Non-Small Cell Lung CancerClinical Cancer Research, 2004
- Targeted Therapies for Cancer 2004American Journal of Clinical Pathology, 2004
- Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumorsMolecular Immunology, 2003
- Human and rodent decay‐accelerating factors (CD55) are not species restricted in their complement‐inhibiting activitiesImmunology, 2000